查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2002818

HIV临床试验市场：按药物类别、试验阶段、最终用户、给药途径、分销管道和患者年龄组划分－2026年至2032年全球市场预测

HIV Clinical Trials Market by Drug Class, Trial Phase, End User, Route Of Administration, Distribution Channel, Patient Age Group - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，爱滋病临床试验市场价值将达到 15.5 亿美元，到 2026 年将成长到 21.6 亿美元，到 2032 年将达到 176 亿美元，复合年增长率为 41.45%。

主要市场统计数据
基准年 2025 15.5亿美元
预计年份：2026年 21.6亿美元
预测年份 2032 176亿美元
复合年增长率 (%) 41.45%

本文简要概述了爱滋病临床试验的现状，重点在于创新驱动因素、营运限制以及相关人员面临的策略挑战。

全球开发安全、有效且可及的爱滋病治疗方法的努力已进入一个需要加速创新和进行务实重新评估的阶段。抗病毒机制的科学进步、试验设计的改进以及对以患者为中心的治疗结果日益重视，都提高了人们对营运效率和公平获取的期望。同时，申办方、研究人员和试验中心面临不断变化的监管要求和复杂的供应链，需要进行适应性规划。

科学突破、监管现代化和数位转型如何重新定义爱滋病临床试验的典范和营运重点。

在科学突破、数位转型和政策演变的推动下，爱滋病临床试验正在经历一场变革。分子病毒学和新型药物疗法的进步正在拓展治疗选择，而适应性试验设计和分散式要素的引入则改变了受试者的招募、监测和留存方式。这些变革正在解决传统的瓶颈问题，并为更有效率地检验更具针对性的假设创造机会。同时，数位化终点、远端监测平台和电子资料收集（EDC）的采用，使得更持续、以患者为中心的评估成为可能，从而减轻了临床试验中心的负担。

本研究评估了美国关税措施和相关贸易政策转变如何重塑爱滋病临床试验的供应链、营运成本和国际合作动态。

美国近期实施的关税措施及相关贸易政策调整，正对爱滋病临床试验生态系统产生显着的间接影响，主要体现在改变上游成本和物流动态，而非直接改变科学典范。对活性成分、专用实验室设备和必要包装组件征收关税，可能会延长临床实验药物生产和临床供应链的采购前置作业时间，并增加常规采购成本。因此，临床试验赞助者和契约製造生产商越来越重视双重采购、库存缓衝以及与报关行更紧密的合作，以确保临床实验进度。

从细分观点治疗领域、试验阶段、医疗保健服务环境、给药途径、通路和病患年龄如何相互交织，进而影响策略性试验选择。

細項分析揭示了不同治疗领域、试验阶段、临床环境、给药途径、通路和患者族群的策略意义各不相同。治疗研发的优先顺序因药物类别而异。病毒进入抑制剂，例如恩韦地肽和马拉维罗克，主要针对早期病毒进入机制，通常需要肠外给药。整合酶链转移抑制剂，例如比克替拉韦、多替拉韦、埃尔维特格拉韦和拉替拉韦，通常用于简化给药方案，但需要密切监测药物交互作用和抗药性。非核苷类逆转录酶抑制剂，例如依非韦伦、依曲韦林、奈韦拉平和利匹韦林，在试验设计中体现了其独特的安全性和中枢神经系统（CNS）耐受性特征，而核苷类逆转录酶抑制剂，例如恩曲他滨、拉米夫定、替诺福韦和齐多夫定，仍然是骨干策略的核心。对于阿扎那韦、达芦那韦、福沙那韦和洛匹那韦等蛋白酶抑制剂，有必要评估可能影响终点选择的代谢和药物依从性因素。

我们在美洲、欧洲、中东和非洲以及亚太地区的营运和监管专业知识将有助于选择最佳临床实验地点并制定实施策略。

区域趋势对试验设计、实施和监管合作有显着影响。儘管美洲地区完善的研究基础设施和成熟的法规结构使得许多申办方能够快速启动试验，但该地区地域的多样性要求对试验地点进行仔细的可行性评估，以确保受试者招募具有代表性并实现公平的试验机会。北美临床试验中心通常主导早期创新，而拉丁美洲各地的试验中心则在真实临床环境中验证疗效和扩大受试者多样性方面发挥着至关重要的作用。

深入了解影响 HIV 临床开发中卓越营运和转换动力的有影响力的赞助商、合作模式和服务供应商。

参与爱滋病临床开发的机构竞争格局复杂多样，既有成熟的製药公司，也有专注于生物製药开发的专业公司、合约研究组织（CRO）、学术联盟，以及提供数据、物流和病人参与等服务供应商。老字型大小企业凭藉其丰富的临床经验和全球开发网络，持续推动大规模的核准申报项目。同时，新兴企业和生技创新者则致力于透过差异化的作用机制和目标患者群体，打造独特的价值提案。

为赞助商和营运经理提供实用建议，以增强 HIV 临床试验中的供应弹性、监管合规性、参与者参与度和共同研究模式。

产业领导者应优先采取一系列切实可行的措施，以增强韧性、加快证据产生并确保公平取得。首先，投资于多元化的供应商网路和合约机制，以确保临床实验药物和关键实验室试剂的持续供应。其次，谨慎地融入分散式试验的要素，以减轻受试者的负担，同时保持严格的监测控制和检验的远端资料收集。

采用透明的、基于三角测量的调查方法，结合一手访谈、文献综述、操作案例研究和严​​格检验，以确保可靠的测试资讯。

本报告的分析是基于三角测量研究方法，该方法结合了对关键意见领袖 (KOL) 的访谈、对同行评审文献和公开监管文件的二手研究，以及对近期 HIV 临床试验项目运作的案例研究。一级资讯来源包括对临床研究人员、试验管理人员、供应链经理和患者咨询委员会代表的结构化访谈，以了解实际挑战和新兴最佳实践。二级资讯来源包括临床试验报告、监管指导文件和调查方法文献，这些文献提供了有关试验设计、安全监测和终点选择的见解。

策略性地整合营运需求、协作方法和以参与者为中心的设计，指导 HIV 临床开发中的有效决策。

整合科学、营运和政策观点，有助于为参与爱滋病临床研发的机构制定一套一致的优先事项。目前最迫切的挑战在于如何将创新的试验设计与实际操作相结合——即利用适应性和分散性要素来提高效率，同时确保资料流的检验和获得监管部门的核准。同样重要的是，要将供应链韧性和供应商管治视为试验可行性的关键组成部分，而非事后补救措施，因为已有研究表明，这些因素可能会延迟受试者招募或干扰检体处理。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：爱滋病临床试验市场：依药物类别划分

  • 入侵抑制剂
    • 恩夫维尔奇德
    • 马拉威罗克
  • 整合酶链转移抑制剂
    • 比克替拉韦
    • 多替拉韦
    • 埃尔维特格拉维尔
    • 拉特格拉维尔
  • 非核苷类逆转录酶抑制剂
    • 依非韦伦
    • 依福西林
    • 奈韦拉平
    • 利匹韦林
  • 核苷类逆转录酶抑制剂
    • 恩曲他滨
    • 拉米夫定
    • 替诺福韦
    • 齐多夫定
  • 蛋白酶抑制剂
    • 阿扎那韦
    • 达芦那韦
    • 福斯帕奈韦
    • 洛匹那韦

第九章 HIV临床试验市场：按阶段分類的临床试验

  • 第一阶段
  • 第二阶段
    • 第二阶段a
    • IIb期
  • 第三阶段
  • 第四阶段

第十章：爱滋病临床试验市场：依最终用户划分

  • 诊所
  • 医院
  • 研究机构
    • 学术机构
    • 合约研究组织（CTA）

第十一章 HIV临床试验市场：依给药途径划分

  • 注射药物
  • 口服
  • 经皮

第十二章 HIV临床试验市场：依通路划分

  • 医院药房
  • 网路药房
  • 零售药房
    • 连锁药局
    • 独立经营药房

第十三章：依病患年龄组别分類的爱滋病临床试验市场

  • 成人版
  • 老年人
  • 儿童

第十四章 HIV临床试验市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 HIV临床试验市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 爱滋病临床试验市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十七章：美国爱滋病临床试验市场

第十八章：中国爱滋病临床试验市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Gilead Sciences, Inc.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Pfizer Inc.
  • Roche Holding AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • ViiV Healthcare Limited
Product Code: MRR-7C50F273957B

The HIV Clinical Trials Market was valued at USD 1.55 billion in 2025 and is projected to grow to USD 2.16 billion in 2026, with a CAGR of 41.45%, reaching USD 17.60 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.55 billion
Estimated Year [2026] USD 2.16 billion
Forecast Year [2032] USD 17.60 billion
CAGR (%) 41.45%

A concise framing of the contemporary HIV clinical trials landscape highlighting innovation drivers, operational constraints, and strategic imperatives for stakeholders

The global effort to develop safe, effective, and accessible HIV therapies has entered a period of intensified innovation and practical recalibration. Scientific advances in antiviral mechanisms, improvements in trial design, and an increasing emphasis on patient-centered outcomes have combined with heightened expectations for operational efficiency and equitable access. Simultaneously, sponsors, investigators, and trial sites face evolving regulatory expectations and supply-chain complexities that require adaptive planning.

This executive summary provides decision-makers with a focused synthesis of the forces shaping contemporary HIV clinical trials. It identifies core scientific and operational drivers, highlights systemic risks that can impede development timelines, and surfaces practical levers stakeholders can use to strengthen program resilience. By integrating clinical, logistical, and policy perspectives, the summary gives leaders a clear vantage point from which to prioritize investments, refine partnerships, and accelerate translational pipelines while maintaining ethical and regulatory rigor.

Throughout, the analysis emphasizes actionable clarity: where to allocate resources to improve recruitment and retention, how to anticipate and manage cross-border operational friction, and which collaborative models have demonstrated the greatest potential to shorten time to reliable evidence without compromising safety or data integrity.

How scientific breakthroughs, regulatory modernization, and digital transformation are collectively redefining HIV clinical trial paradigms and operational priorities

HIV clinical trials are being reshaped by a conjunction of scientific breakthroughs, digital transformation, and policy evolution. Advances in molecular virology and novel drug modalities have expanded the therapeutic toolkit, while adaptive trial designs and decentralized elements have begun to change how participants are recruited, monitored, and retained. These shifts reduce conventional bottlenecks and create opportunities to test more targeted hypotheses with greater efficiency. At the same time, the adoption of digital endpoints, remote monitoring platforms, and electronic source data capture is enabling more continuous, patient-centric assessments and reducing site burden.

Regulatory agencies worldwide are also signaling increased openness to innovative approaches, particularly when studies are designed with clear risk mitigation and robust data quality controls. This regulatory receptivity, however, comes with heightened expectations around data provenance, device validation, and participant protections, which require early dialog and alignment. Moreover, the emergence of public-private partnerships and academic-industry consortia is accelerating translational research while raising important questions about data sharing, IP stewardship, and equitable distribution of benefits.

As these transformative forces coalesce, stakeholders must balance speed with rigor, and innovation with access. Pragmatic integration of new technologies, coupled with deliberate stakeholder engagement and strengthened supply resilience, will determine which programs realize their potential to deliver meaningful clinical advances.

Assessing how United States tariff measures and related trade policy shifts are reshaping HIV clinical trial supply chains, operational costs, and international collaboration dynamics

Recent tariff measures implemented by the United States and related trade policy shifts have had a pronounced indirect effect on the HIV clinical trials ecosystem, primarily by altering upstream cost and logistics dynamics without directly changing scientific paradigms. Tariffs on active pharmaceutical ingredients, specialized laboratory equipment, and essential packaging components can increase procurement lead times and elevate routine sourcing costs for investigational product manufacturing and clinical supply chains. In turn, sponsors and contract manufacturers have increasingly prioritized dual sourcing, inventory buffering, and closer coordination with customs brokers to preserve study timelines.

Beyond material costs, tariffs can complicate cross-border collaborations that underpin global trial networks. Research sites that rely on imported diagnostic reagents or cold-chain logistics may experience episodic shortages or face unexpected customs delays, which can disrupt specimen handling and compromise data integrity if not proactively managed. Additionally, tariff-driven cost pressure can intensify negotiations around pricing for ancillary services, leading some sponsors to re-evaluate the geographic distribution of laboratory services, central lab consolidation, or greater reliance on regional suppliers.

Importantly, tariff effects intersect with policy and operational responses: regulatory flexibility for alternative supplier validation, accelerated import permits for clinical supplies, and contractual clauses that allocate risk among sponsors and providers. Looking ahead, industry leaders should anticipate that tariff volatility will remain a factor in supply planning and should incorporate scenario-based risk assessments, strengthened supplier governance, and enhanced visibility into end-to-end logistics to shield clinical programs from avoidable disruption.

Segmentation-driven perspectives on how therapeutic class, trial phase, care setting, administration route, distribution channel, and patient age intersect to shape strategic trial choices

Segmentation analysis reveals differentiated strategic implications across therapeutic categories, trial stages, care settings, administration routes, distribution channels, and patient demographics. When classified by drug class, therapeutic development priorities vary: Entry Inhibitors such as enfuvirtide and maraviroc focus on targeting initial viral entry mechanisms and often require parenteral administration strategies, whereas Integrase Strand Transfer Inhibitors including bictegravir, dolutegravir, elvitegravir, and raltegravir frequently underpin regimen simplification efforts and demand attention to drug-drug interactions and resistance surveillance. Non-Nucleoside Reverse Transcriptase Inhibitors like efavirenz, etravirine, nevirapine, and rilpivirine bring their own safety and CNS tolerability profiles to trial design, while Nucleoside Reverse Transcriptase Inhibitors-emtricitabine, lamivudine, tenofovir, and zidovudine-remain central to backbone strategies. Protease Inhibitors such as atazanavir, darunavir, fosamprenavir, and lopinavir require evaluation of metabolic and adherence considerations that influence endpoint selection.

By trial phase, the emphasis shifts from safety and proof-of-concept in Phase I and Phase IIa/IIb to broader efficacy and comparative endpoints in Phase III and real-world safety in Phase IV. Trial phase influences sample size, operational complexity, and monitoring intensity, which in turn affects site selection and patient engagement strategies. End-user segmentation underscores different operational models: clinics and hospitals deliver point-of-care recruitment and integrated monitoring, while research institutes, including academic centers and contract research organizations, often provide specialized expertise and centralized data oversight.

Route of administration considerations-injectable, oral, and transdermal-drive both patient acceptability and supply-chain requirements, with injectables requiring cold-chain or sterile compounding competencies and oral regimens emphasizing adherence support. Distribution channel nuances across hospital pharmacies, online pharmacies, and retail pharmacies, with retail further divided into chain and independent outlets, affect dispensing workflows and post-trial access planning. Finally, patient age groups-adult, geriatric, and pediatric-necessitate tailored safety monitoring, consent processes, and endpoint selection to ensure that trials generate clinically actionable evidence for each population segment.

Regional operational and regulatory insights across the Americas, Europe Middle East & Africa, and Asia-Pacific that inform optimized trial site selection and execution strategies

Regional dynamics exert a strong influence on trial design, operational execution, and regulatory engagement. In the Americas, established research infrastructures and mature regulatory frameworks facilitate rapid study start-up for many sponsors, yet geographic diversity within the region necessitates careful site feasibility assessments to ensure representative enrollment and equitable access. Clinical sites in North America often lead in early-phase innovation, while sites across Latin America play a critical role in demonstrating real-world effectiveness and expanding participant diversity.

Europe, Middle East & Africa presents a heterogeneous regulatory landscape where harmonization initiatives coexist with localized requirements. Sponsors operating across this expanse must balance the advantages of experienced academic centers and large patient pools against variable ethics review timelines and administrative processes. In many jurisdictions, investment in capacity building, standardized data-capture practices, and early regulatory dialogue proves essential to mitigate delays and maintain data quality.

Asia-Pacific combines rapidly growing clinical research capacity with variable reimbursement and regulatory pathways. The region offers opportunities for accelerated enrollment and access to diverse patient populations, but success depends on culturally adapted recruitment strategies, local investigator engagement, and robust supply-chain planning to navigate importation and site provisioning. Across all regions, aligning trial architecture with local clinical practice, engaging community stakeholders, and investing in site training and quality oversight are pivotal to generating high-integrity, generalizable evidence.

Intelligence on influential sponsors, collaborative models, and service providers that are shaping operational excellence and translational momentum in HIV clinical development

The competitive landscape of organizations involved in HIV clinical development reflects a mix of established pharmaceutical sponsors, specialist biologics developers, contract research organizations, academic consortia, and service providers focused on data, logistics, and patient engagement. Established companies continue to leverage deep clinical experience and global development networks to advance large-scale registrational programs, while emerging players and biotech innovators concentrate on differentiated mechanisms of action and targeted populations to carve niche value propositions.

Collaborative models-ranging from strategic alliances between industry and academic centers to multi-stakeholder consortia that share protocols and pooled data-have become more prominent as a way to spread risk and accelerate evidence generation. Contract research organizations and specialty service providers play a critical role in operationalizing complex trial elements such as long-acting injectable manufacturing, cold-chain management, and decentralized trial components. Technology vendors that provide validated electronic data capture, remote monitoring, and interoperable laboratory information systems are increasingly integral to ensuring data integrity and regulatory compliance.

Leadership in this ecosystem depends on integrating scientific clarity with operational excellence. Organizations that combine precise mechanistic hypotheses with robust site governance, flexible supply arrangements, and community-informed recruitment strategies will be best positioned to execute high-quality trials that deliver clinically meaningful outcomes.

Actionable recommendations for sponsors and operational leaders to enhance supply resilience, regulatory alignment, participant engagement, and collaborative research models in HIV trials

Industry leaders should prioritize a set of pragmatic, actionable measures to increase resilience, accelerate evidence generation, and ensure equitable access. First, invest in diversified supplier networks and contractual mechanisms that preserve continuity of investigational product supply and critical laboratory reagents. Second, embed decentralized trial elements judiciously to reduce participant burden while maintaining rigorous monitoring controls and validated remote data capture.

Third, engage regulators and ethics committees early and often to align on adaptive designs, biomarker endpoints, and safety monitoring frameworks; proactive engagement reduces cycles and increases the likelihood of regulatory acceptance. Fourth, design recruitment and retention strategies that are community-informed and culturally sensitive, particularly when trials span multiple regions and demographic groups. Fifth, implement data governance practices that ensure interoperability, traceability, and rapid auditability to meet both regulatory expectations and publication standards.

Finally, cultivate collaborative consortia and public-private partnerships that share noncompetitive data and infrastructure, thereby lowering barriers to entry for smaller developers and accelerating comparative effectiveness research. By integrating these actions into program planning, leaders can reduce operational risk, optimize resource allocation, and increase the probability that trials generate clinically consequential and generalizable results.

A transparent, triangulated research methodology that integrates primary interviews, literature review, operational case studies, and rigorous validation to ensure reliable trial intelligence

The analysis underpinning this report draws on a triangulated research approach that combines primary interviews with key opinion leaders, secondary review of peer-reviewed literature and public regulatory documents, and operational case studies of recent HIV trial programs. Primary inputs include structured interviews with clinical investigators, trial operations leaders, supply-chain managers, and patient-advisory representatives to capture frontline challenges and emergent best practices. Secondary sources encompass clinical study reports, regulatory guidance documents, and methodological literature that inform trial design, safety monitoring, and endpoint selection.

Analytical frameworks employed include risk mapping for supply-chain vulnerability, decision-tree modeling for site selection, and stakeholder impact matrices to prioritize mitigation strategies. Validation steps incorporated cross-checks between interview insights and documented trial outcomes, as well as iterative reviews with external subject matter experts to ensure interpretive accuracy. Quality controls comprised source verification for all cited regulatory positions and internal audit trails for interview transcripts and synthesis notes.

Limitations are acknowledged, including the dynamic nature of trade policy and regulatory guidance, which may evolve after the report's compilation. To mitigate these constraints, the methodology emphasizes transparent assumptions, scenario-based analyses, and clear delineation between observed practice and expert projection, thereby enabling readers to adapt the findings to their specific operational contexts.

A strategic synthesis that integrates operational imperatives, collaborative approaches, and participant-centered design to guide effective HIV clinical development decisions

Bringing together scientific, operational, and policy perspectives yields a coherent set of priorities for organizations engaged in HIV clinical development. The most immediate imperative is to harmonize innovative trial design with pragmatic execution: leverage adaptive and decentralized elements to increase efficiency while ensuring validated data flows and regulatory acceptability. Equally important is treating supply-chain resilience and supplier governance as integral components of trial feasibility rather than as afterthoughts, given their demonstrated capacity to delay enrollment and compromise specimen handling.

Strategically, sponsors should pursue collaborative architectures that combine the strengths of industry, academia, and specialized service providers to accelerate translational pathways and broaden access to diverse participant cohorts. Operational leaders must invest in digital and human infrastructure that supports remote monitoring, standardized laboratory practices, and culturally tailored recruitment. Finally, sustained engagement with regulators and community stakeholders will smooth the path for novel endpoints and increase public trust in trial results.

Taken together, these imperatives set a practical agenda: integrate scientific ambition with operational rigor, anticipate and mitigate supply and policy risks, and center participant needs in study design. Organizations that execute along these lines will be better positioned to deliver robust, actionable evidence that advances therapy and access for people living with HIV.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. HIV Clinical Trials Market, by Drug Class

  • 8.1. Entry Inhibitors
    • 8.1.1. Enfuvirtide
    • 8.1.2. Maraviroc
  • 8.2. Integrase Strand Transfer Inhibitors
    • 8.2.1. Bictegravir
    • 8.2.2. Dolutegravir
    • 8.2.3. Elvitegravir
    • 8.2.4. Raltegravir
  • 8.3. Non-Nucleoside Reverse Transcriptase Inhibitors
    • 8.3.1. Efavirenz
    • 8.3.2. Etravirine
    • 8.3.3. Nevirapine
    • 8.3.4. Rilpivirine
  • 8.4. Nucleoside Reverse Transcriptase Inhibitors
    • 8.4.1. Emtricitabine
    • 8.4.2. Lamivudine
    • 8.4.3. Tenofovir
    • 8.4.4. Zidovudine
  • 8.5. Protease Inhibitors
    • 8.5.1. Atazanavir
    • 8.5.2. Darunavir
    • 8.5.3. Fosamprenavir
    • 8.5.4. Lopinavir

9. HIV Clinical Trials Market, by Trial Phase

  • 9.1. Phase I
  • 9.2. Phase II
    • 9.2.1. Phase IIa
    • 9.2.2. Phase IIb
  • 9.3. Phase III
  • 9.4. Phase IV

10. HIV Clinical Trials Market, by End User

  • 10.1. Clinics
  • 10.2. Hospitals
  • 10.3. Research Institutes
    • 10.3.1. Academic Institutes
    • 10.3.2. Contract Research Organizations

11. HIV Clinical Trials Market, by Route Of Administration

  • 11.1. Injectable
  • 11.2. Oral
  • 11.3. Transdermal

12. HIV Clinical Trials Market, by Distribution Channel

  • 12.1. Hospital Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies
    • 12.3.1. Chain Pharmacies
    • 12.3.2. Independent Pharmacies

13. HIV Clinical Trials Market, by Patient Age Group

  • 13.1. Adult
  • 13.2. Geriatric
  • 13.3. Pediatric

14. HIV Clinical Trials Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. HIV Clinical Trials Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. HIV Clinical Trials Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States HIV Clinical Trials Market

18. China HIV Clinical Trials Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. AbbVie Inc.
  • 19.6. Gilead Sciences, Inc.
  • 19.7. Johnson & Johnson
  • 19.8. Merck & Co., Inc.
  • 19.9. Moderna, Inc.
  • 19.10. Pfizer Inc.
  • 19.11. Roche Holding AG
  • 19.12. Sanofi S.A.
  • 19.13. Takeda Pharmaceutical Company Limited
  • 19.14. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HIV CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HIV CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ENFUVIRTIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY MARAVIROC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY BICTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DOLUTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ELVITEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RALTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EFAVIRENZ, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ETRAVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NEVIRAPINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RILPIVIRINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY EMTRICITABINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LAMIVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TENOFOVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ZIDOVUDINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ATAZANAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DARUNAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY FOSAMPRENAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY LOPINAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PHASE IV, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY TRANSDERMAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY CHAIN PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 139. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 140. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY INDEPENDENT PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 143. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 146. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GERIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 149. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 153. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 155. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 156. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 157. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 158. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 159. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 160. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 161. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 163. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 165. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 166. AMERICAS HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 170. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 171. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 174. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 176. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 178. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 180. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 187. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 188. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 189. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 190. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 192. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 194. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 196. LATIN AMERICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 226. EUROPE HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 238. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 239. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 241. MIDDLE EAST HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 256. AFRICA HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL HIV CLINICAL TRIALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 288. GCC HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 289. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 291. GCC HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 292. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 295. GCC HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 296. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 297. GCC HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 300. GCC HIV CLINICAL TRIALS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 301. GCC HIV CLINICAL TRIALS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 302. GCC HIV CLINICAL TRIALS MARKET SIZE, BY PATIENT AGE GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 304. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 305. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ENTRY INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 306. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY INTEGRASE STRAND TRANSFER INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PROTEASE INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY PHASE II, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 315. EUROPEAN UNION HIV CLINICAL TRIALS MARKET SIZE, BY DI